-
The anti-epidemic hero assumed the new National Bureau of Disease Control and Prevention, and the adjustment of the disease control system "breaks"?
Time of Update: 2021-07-07
Its responsibilities are to formulate major disease prevention and control plans, national immunization plans, and intervention measures for public health problems that seriously endanger people’s health and organize their implementation, improve the disease prevention and control system, and undertake infections.
-
BeiGene Announces Financial Results for the First Quarter of 2021
Time of Update: 2021-07-07
BeiGene is a global biotechnology company focusing on the development and commercialization of innovative drugs worldwide . The company today announced recent business highlights, expected mileston
-
Osaikang obtained the first domestic approval for posaconazole injection and has a reliable plan for sequential prevention and treatment of IFD
Time of Update: 2021-07-07
1. Ixuanao® enteric-coated tablets and injections have been successively approved to provide the most reliable solution for the sequential prevention and treatment of invasive fungal disease (IFD) in clinical practice Posaconazole is the latest generation of triazole antifungal drugs and the antifungal drug with the broadest antibacterial spectrum so far .
-
China will join Galmed's Phase 3 ARMOR study on Aramchol's treatment of NASH and fibrosis
Time of Update: 2021-07-07
The company announced today that the National Medical Products Administration (NMPA) of China has approved Galmed's application for a new drug clinical trial application (IND) for the Phase 3 ARMOR study of Aramchol for the treatment of NASH and fibrosis .
-
The State Food and Drug Administration approves Baihuize for the treatment of patients with advanced ovarian cancer who have received treatment
Time of Update: 2021-07-07
The company announced today that the National Medical Products Administration (NMPA) of China has granted its PARP inhibitor Baihuize® (Pamiparib) conditional approval for the treatment of at least two lines of chemotherapy with germline BRCA ( gBRCA) mutations in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer .
-
Fosun and Yuyuan Co., Ltd. enter into equity and creditor's rights transfer contract
Time of Update: 2021-07-07
for a total consideration of approximately RMB 176 million, and to transfer and sell the creditor's rights to Yuyuan Co.
Foshan Chanxi It is a company established to carry out the "Zen Medical Health City Complex Project" .
-
Cimetidine Tablets, a subsidiary of China Pharmaceuticals, passed the consistency evaluation
Time of Update: 2021-07-07
, has obtained the "Notice of Approval of Drug Supplement Application" for cimetidine tablets approved and issued by the National Medical Products Administration.
100), after review, this product has passed the quality and efficacy consistency evaluation of generic drugs .
-
Danaher Announces First Quarter 2021 Results
Time of Update: 2021-07-07
9 billion, of which non-GAAP core revenue, including Cytiva, increased by 30.
For the second quarter of 2021, the company expects non-GAAP core revenue growth to be around 25% .
Our record revenue performance has promoted strong earnings per share growth and cash flow generation.
-
Fuan Pharmaceutical's Rocuronium Bromide Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-07-07
, a wholly-owned subsidiary of Fuan Pharmaceutical Group, had recently received a supplementary drug application approval notice issued by the National Medical Products Administration.
Its product rocuronium Ammonium injection passed the quality and efficacy consistency evaluation of generic drugs .
-
Corning Jerry's PD-L1/CTLA-4 bispecific antibody KN046 and Pfizer Inleader (Axitinib) jointly carry out Phase II clinical trials
Time of Update: 2021-07-07
Corning Jereh Biopharmaceuticals announced that it has reached a clinical trial and drug supply cooperation with Pfizer to evaluate the effectiveness and safety of KN046 in combination with Inlead® (axitinib) for the first-line treatment of non-small cell lung cancer (NSCLC) Sex .
-
Sansheng Guojian's independent research and development of SSGJ-612 clinical trial for injection was approved
Time of Update: 2021-07-07
Professor Zhang Jian, deputy director of the Department of Oncology of Fudan University Cancer Hospital and medical director of the Phase I Clinical Research Center, said: "I am very pleased that the SSGJ-612 clinical trial application has been approved, which brings us more possibilities for anti-HER2 treatment of tumors .
-
Buchang Pharmaceuticals lacosamide tablets obtained a drug registration certificate issued by the State Food and Drug Administration
Time of Update: 2021-07-07
, a wholly-owned subsidiary of the company, has recently received the "Drug Registration Certificate" for lacosamide tablets approved and issued by the National Medical Products Administration .
14 million in research and development expenses on lacosamide tablets .
-
Golly announces that the subcutaneous injection of PD-L1 antibody ASC22 Phase IIa hepatitis B trial has achieved good results
Time of Update: 2021-07-07
The primary efficacy endpoint of the trial was the decline of hepatitis B surface antigen during the 12-week follow-up after a single dose .
Of the nine patients treated with ASC22, eight showed some degree of hepatitis B surface antigen decline at the end of the 12-week follow-up .
-
Lansoprazole for injection of cucurbitwa obtained the drug registration certificate
Time of Update: 2021-07-07
On April 30, Huluwa announced that it had recently received the "Drug Registration Certificate" for lansoprazole for injection approved and issued by the State Food and Drug Administration .
-
Qiming Medical's TriGUARD3 Chinese registered clinical trial successfully completed the first case enrollment
Time of Update: 2021-07-07
TriGUARD3TM completely covers the innominate artery of the aortic branch, the left carotid artery and the subclavian artery openings, which can reduce embolic materials entering the brain, thereby minimizing the risk of brain damage during transcatheter aortic valve replacement (TAVR) surgery , Fully protect the brain tissue .
-
WuXi AppTec's growth rate in the first quarter of 2021 hits a record high
Time of Update: 2021-07-07
, a company capable of providing comprehensive and integrated new drug R&D and production services and technology platform for the global biomedical industry, released the first quarter report of 2021 .
-
Aimike, which only sells hyaluronic acid, has doubled its profit and income in the first quarter.
Time of Update: 2021-07-07
According to its 2021 annual report, this type of product achieved operating income of 450 million yuan, an increase of 82.
According to its annual report, gel injection products will reach 252 million yuan in 2020, accounting for 35.
-
Renfu Medicine's midazolam oral solution was approved
Time of Update: 2021-07-07
, a subsidiary of the company, has recently received the "Drug Registration Certificate" for midazolam oral solution approved and issued by the State Drug Administration .
-
Leading Biotech and Baitu Biotech reached ecological cooperation
Time of Update: 2021-07-07
As the first biocomputing-driven life science platform company in China, we are very pleased to reach an all-round ecological cooperation with Leadstar Bio, using AI and computing's data mining capabilities to jointly promote the clinical progress and scientific research transformation of innovative drugs .
-
Rongchang, Lepu, and Kelun are enthusiastic about research and development.
Time of Update: 2021-07-07
ADC drugs combine the high specificity of monoclonal antibody drugs with the high activity of small molecule cytotoxic drugs to improve the targeting of tumor drugs and reduce toxic side effects .
